A Phase 1 interventional study of QLS7305 Injection and Placebo Control in Healthy Volunteers - Male and Female, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China. The main questions it aims to answer are:
What is the safety and tolerability profile of single and multiple subcutaneous doses of QLS7305 in healthy adults? What are the pharmacokinetic (PK) characteristics of QLS7305 and its major metabolites? What are the pharmacodynamic (PD) effects of QLS7305 on the complement system (e.g., serum C3 levels and complement activity)? Does QLS7305 induce an immunogenic response (anti-drug antibodies)? What is the effect of QLS7305 on the QTc interval? Investigators will compare different dose levels of QLS7305 to a placebo group to see the effects on safety, tolerability, and the measured parameters.
Participants will:
Be enrolled in one of two parts of the study:
Part A (Single Ascending Dose): Receive a single dose of QLS7305 or placebo. Part B (Multiple Ascending Dose): Receive multiple doses of QLS7305 or placebo (doses selected based on Part A results).
Receive prophylactic antibiotics (Penicillin V) after the first dose until their serum complement C3 level recovers, as a safety precaution.
Undergo close safety monitoring throughout the study, including a follow-up period of up to 337 days to ensure safety parameters return to acceptable levels.
The primary objective of this study is to evaluate the safety and tolerability of QLS7305 Injection subcutaneously administered to healthy adults. The secondary objectives are to evaluate the pharmacokinetic (PK) characteristics, the pharmacodynamic (PD) characteristics, the immunogenicity and the effect of subcutaneous injection of QLS7305 injection on QTc interval in healthy adult participants.
This study consists of two parts:
Participants will be screened from Day -77 to Day -2. After providing informed consent, participants will receive vaccinations against Neisseria meningitidis and Streptococcus pneumoniae at least two weeks prior to dosing. Eligible participants will be admitted to the clinic on Day -1 for baseline assessments. Dosing will occur on Day 1 (for both parts) and additionally on Day 29 (for Part B). Intensive safety and PK assessments will be performed. Participants will receive prophylactic antibiotic treatment (e.g., Penicillin V) post-dose, which may be discontinued based on the investigator's assessment of serum complement C3 levels and safety risk.
A long-term follow-up period of up to Day 337 post-dose is planned to monitor safety, PD markers (C3, CP, AP), and immunogenicity. Participants with suppressed complement levels at Day 169 will undergo additional follow-up every 8 weeks until recovery (or until Day 337). After Day 337, the unblinded physician may arrange for further monitoring of specific participants if complement levels remain below predefined recovery thresholds.
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aged between 18 and 55 years (inclusive) Physical examination, vital signs, laboratory tests, 12-lead , and imaging findings are within normal ranges.
Body weight ≥50 kg for males and ≥45 kg for females, with a BM) between 18.0 and 28 kg/m² (inclusive).
Willing or has complied with the administration of meningococcal and pneumococcal vaccines as required by the protocol.
No plan to donate sperm or ova, no pregnancy plan, and voluntarily agrees to use effective methods from the signing of the ICF until 12 months after administration of the product.
Able to understand and comply with the study procedures, voluntarily participate in the trial, and provide written .
Exclusion Criteria:
History of food or drug allergy, and/or known allergy to GalNAc. History of definite infection with encapsulated bacteria within 6 months prior to screening.
History of recurrent or chronic infection within 3 months prior to screening. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection within 1 month prior to baseline.
Any disease at screening that, in the investigator's judgment, could affect the study data.
History of . Any condition that may affect drug absorption. History of splenectomy or congenital asplenia. History of congenital or acquired complement deficiency or disorder. History of allergic diseases (e.g., allergic asthma, allergic rhinitis).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QLS7305 Injection
Drug: QLS7305 Injection
Placebo
Drug: Placebo Control
QLS7305 Injection
Also known as: QLS7305
The placebo is a sterile solution that matches the appearance, volume, and packaging of the QLS7305 injection. It contains no active pharmaceutical ingredient and is administered subcutaneously following the same dosing schedule as the active comparator (single or multiple doses).
Also known as: Placebo
Incidence and severity of TEAEs
Time frame: 337 days
Plasma and urine concentrations of QLS7305
Time frame: 337 days
Relationship between plasma concentration of QLS7305 and the change in QTc interval.
Time frame: D3
No study locations are listed for this record.
Plan to share: Yes — Anonymized individual participant data that underlie the results reported in the primary publication (for the primary and secondary endpoints).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Beginning 12 months after the primary publication and ending 5 years after the end of the study.
Access criteria: Individual participant data that underlie the results reported in this publication, after de-identification (text, tables, figures, and appendices) will be available. Proposals should be directed to jing16.wang@qilu-pharma.com. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Dec 2027, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Pharmaceutical Co., Ltd. →